半乳糖凝集素-3（Gal-3）及核因子κB（NFκB）通路相关因子在上皮性卵巢癌中的表达及临床意义
Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma.
作者信息
Luk Hiu-Mei, Wang Dong-Yan, Xie Ling-Ling, Liu Xun-Yun, Xu Guo-Cai, Lu Huai-Wu
机构信息
Department of Obstetrics and Gynaecology, Kwong Wah Hospital Hong Kong SAR, China.
Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou 510120, China.
出版信息
Int J Clin Exp Pathol. 2020 May 1;13(5):1197-1205. eCollection 2020.
OBJECTIVE
To explore the expression and clinical significance of Gal-3 and NFκB pathway related factors in epithelial ovarian carcinoma cells.
METHODS
99 histologic specimens of epithelial ovarian cancer and 20 normal ovarian histologic specimens were collected, and the expressions of Gal-3, IκB and p65 were detected by immunohistochemistry. Their relationship with clinical characteristics was analyzed.
RESULTS
The expression of Gal-3 and p65 was negatively correlated with the overall survival rate (P<0.05), while the expression of IκB was positively correlated with the overall survival rate (P<0.05). Expression of Gal-3, p65 and IκB were found associated with EOC platinum resistance (P<0.05), and expression of Gal-3 and p65 correlated with pathologic grading (P<0.05). IκB and Gal-3 were associated with the recurrence of EOC (P<0.05). IκB may be related to clinical stage (P<0.05). Multivariate analysis results showed that abnormal expression of Gal-3 may be an independent prognostic risk factors for the drug resistance to platinum-based chemotherapy (95% CI=5.336~34.112, P<0.05). The expression of Gal-3, p65, and IκB can be clinical immunohistochemical indicators that determine the prognosis of EOC, but the amount of Gal-3 expression was related to the epithelial ovarian cancer's pathologic type and overall survival, which suggested that Gal-3 can be used as a prognostic factor in epithelial ovarian cancer.
CONCLUSION
Targeted therapy of Gal-3 may become an effective potential new method against epithelial ovarian cancer.
目的
探讨半乳糖凝集素-3（Gal-3）和核因子κB（NFκB）通路相关因子在上皮性卵巢癌细胞中的表达及临床意义。
方法
收集99例上皮性卵巢癌组织标本和20例正常卵巢组织标本，采用免疫组织化学法检测Gal-3、IκB和p65的表达，并分析其与临床特征的关系。
结果
Gal-3和p65的表达与总生存率呈负相关（P<0.05），而IκB的表达与总生存率呈正相关（P<0.05）。Gal-3、p65和IκB的表达与上皮性卵巢癌铂耐药相关（P<0.05），Gal-3和p65的表达与病理分级相关（P<0.05）。IκB和Gal-3与上皮性卵巢癌复发相关（P<0.05）。IκB可能与临床分期有关（P<0.05）。多因素分析结果显示，Gal-3异常表达可能是铂类化疗耐药的独立预后危险因素（95%CI=5.336~34.112，P<0.05）。Gal-3、p65和IκB的表达可作为判断上皮性卵巢癌预后的临床免疫组化指标，但Gal-3的表达量与上皮性卵巢癌的病理类型及总生存有关，提示Gal-3可作为上皮性卵巢癌的预后因素。
结论
Gal-3靶向治疗可能成为治疗上皮性卵巢癌的一种有效的潜在新方法。
Zotero 插件